Tianyin Pharmaceutical Co., Inc. (TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), said that the discussions between itself and Buchang Pharma (www.buchang.com) have developed towards increasing the percentage of ownership by Buchang Pharma in the Tianyin-Buchang Alliance joint venture. The total registered capital for the joint venture is approximately $33 million, of which TPI’s wholly owned subsidiary Chengdu Tianyin Pharmaceutical Co., Ltd. owns 95% and Buchang Pharma owns 5%. These discussions follow the completion of construction and the subsequent successful GMP certification (Certification No.: SC20140067, valid till July 1, 2020) according to the latest GMP standards at the company’s new manufacturing Qionglai Facility (QLF). The integration of the TPI-Buchang Pharma sales network platform is making progress and the production is ongoing at the QLF after further upgrades on both mTCM extraction and formulation technologies supported by Buchang Pharma.